More than 100,000 screened compounds yielded GHP-88310, which cut viral replication and kept all treated ferrets alive when dosing began three days after infection, according to a May 22 Science Advances report.
The candidate targets a viral protein shared across the Orthoparamyxovirus family, raising hopes it could work not only against measles but also against Nipah and human parainfluenza viruses.
That search has gained urgency as measles resurges: the United States had 2,073 cases as of June 11, with over 90% in unvaccinated people or those with unknown vaccination status.
No measles antivirals are approved, and human trials remain difficult because outbreaks are unpredictable, vaccine access is uneven, and enrolling unvaccinated children instead of offering shots raises ethical problems.
Plemper's team plans to test the drug first against human parainfluenza virus type 3, hoping success there could eventually support use during measles outbreaks as a backup to vaccination.
With a highly effective vaccine, why is the world now racing to create expensive measles cures?
Can new 'on-demand immunity' therapies protect vulnerable infants before they can be vaccinated?
America’s Measles Emergency: Falling Immunity, Outbreaks, and the Hope of GHP-88310
Overview
The United States is facing a growing measles crisis, with ongoing outbreaks and a year of continuous transmission raising the risk of losing its measles elimination status. As of June 2026, public health officials are concerned that measles could become endemic again, undoing decades of progress. The Pan-American Health Organization will review the U.S. elimination status in November 2026, a decision influenced by the sustained spread of measles, especially in areas like Texas where cases have persisted since January 2025. This situation highlights the urgent need for strong vaccination efforts and effective public health strategies.